TY  - INPR
ID  - discovery10161377
N1  - Copyright © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. This is an open access article under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
SN  - 0885-3185
JF  - Movement Disorders
AV  - public
N2  - BACKGROUND: MOXIe was a two-part study evaluating the safety and efficacy of omaveloxolone in patients with Friedreich's ataxia, a rare, progressive neurological disease with no proven therapy. MOXIe part 2, a randomized double-blind placebo-controlled trial, showed omaveloxolone significantly improved modified Friedreich's Ataxia Rating Scale (mFARS) scores relative to placebo. Patients who completed part 1 or 2 were eligible to receive omaveloxolone in an open-label extension study. OBJECTIVE: The delayed-start study compared mFARS scores at the end of MOXIe part 2 with those at 72?weeks in the open-label extension period (up to 144?weeks) for patients initially randomized to omaveloxolone versus those initially randomized to placebo. METHODS: We performed a noninferiority test to compare the difference between treatment groups (placebo to omaveloxolone versus omaveloxolone to omaveloxolone) using a single mixed model repeated measures (MMRM) model. In addition, slopes of the change in mFARS scores were compared between both groups in the open-label extension. RESULTS: The noninferiority testing demonstrated that the difference in mFARS between omaveloxolone and placebo observed at the end of placebo-controlled MOXIe part 2 (-2.17?±?1.09 points) was preserved after 72?weeks in the extension (-2.91?±?1.44 points). In addition, patients previously randomized to omaveloxolone in MOXIe part 2 continued to show no worsening in mFARS relative to their extension baseline through 144?weeks. CONCLUSIONS: These results support the positive results of MOXIe part 2 and indicate a persistent benefit of omaveloxolone treatment on disease course in Friedreich's ataxia. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Y1  - 2022/11/29/
PB  - Wiley
A1  - Lynch, David R
A1  - Chin, Melanie P
A1  - Boesch, Sylvia
A1  - Delatycki, Martin B
A1  - Giunti, Paola
A1  - Goldsberry, Angie
A1  - Hoyle, J Chad
A1  - Mariotti, Caterina
A1  - Mathews, Katherine D
A1  - Nachbauer, Wolfgang
A1  - O'Grady, Megan
A1  - Perlman, Susan
A1  - Subramony, SH
A1  - Wilmot, George
A1  - Zesiewicz, Theresa
A1  - Meyer, Colin J
UR  - https://doi.org/10.1002/mds.29286
TI  - Efficacy of Omaveloxolone in Friedreich's Ataxia: Delayed-Start Analysis of the MOXIe Extension
ER  -